Aciont, Inc. is dedicated to advancing vision research and revolutionizing noninvasive ocular therapeutics. Their primary objective is to equip ophthalmology professionals with greater flexibility and a wider range of treatment options to ensure the best possible care for their patients. The company boasts a highly skilled research team that is committed to developing innovative, noninvasive therapies for sight-threatening diseases affecting both the front and back of the eye. Their work addresses the challenges associated with drug transport and controlled release in a broad spectrum of ocular diseases.

Tags

Eye Diseases

Congenital Disorders

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1
Unknown	1

Drugs associated with Aciont, Inc.

DSP-Visulex

Target-

Mechanism-

Active Org.

Aciont, Inc.

Originator Org.

Aciont, Inc.

Active Indication

Uveitis, Anterior [+2]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

AMD program

Target-

Mechanism-

Active Org.

Aciont, Inc.

Originator Org.

Aciont, Inc.

Active Indication

Age Related Macular Degeneration

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Aciont, Inc.

NCT02309385

/ CompletedPhase 1/2

A Randomized, Parallel Group, Double-masked, Active-controlled Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of Dexamethasone Sodium Phosphate Visulex System for the Treatment of Non-infectious Anterior Uveitis

The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.

Start Date01 Oct 2014

Sponsor / Collaborator

Aciont, Inc.

[+1]

100 Clinical Results associated with Aciont, Inc.

0 Patents (Medical) associated with Aciont, Inc.

Literatures (Medical) associated with Aciont, Inc.

01 May 2020·Journal of Ocular Pharmacology and TherapeuticsQ4 · MEDICINE

Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules

Q4 · MEDICINE

Article

Author: Higuchi, John W. ; Ambati, Balamurali ; Molokhia, Sarah ; Butler, Charlotte ; Higuchi, William I. ; Papangkorn, Kongnara ; Li, S. Kevin ; Brar, Balbir

Purpose: The objectives were to investigate the effect of transscleral iontophoresis of macromolecules in vitro and in vivo, to study the importance of electroosmosis on macromolecules of low charge to mass ratio, and to evaluate transscleral iontophoresis efficacy in a choroidal neovascularization (CNV) animal model. Methods: Through in vitro transport experiments, the permeability coefficients of macromolecules [eg, immunoglobulin G (IgG), dextran 70 kDa] were determined under different conditions. The effect of ionic strength formulations and iontophoretic conditions was studied on the distribution of IgG and bevacizumab into the eye in vivo. Magnetic resonance imaging (MRI) was utilized to evaluate in vivo real time distribution of gadolinium-labeled albumin (Galbumin) following iontophoresis. The efficacy between no treatment, intravitreal injection (IVT), and iontophoresis of bevacizumab on a CNV model of subretinal injection of adeno-associated virus encoding human VEGF-165 was investigated. Results: The permeability data suggested a significant effect of ionic strength on the iontophoretic transport of macromolecules. Transscleral iontophoresis of IgG at 4 mA with a low ionic strength formulation was about 600 times greater than passive diffusion and 14-fold over a conventional formulation in vitro. Approximately 0.6 mg of bevacizumab can be delivered into the rabbit eye in vivo with a 20-min treatment of iontophoresis. MRI showed that Galbumin was in the posterior tissues after iontophoresis. In the CNV model, the iontophoresis and IVT methods of bevacizumab delayed retinal neovascularization by 4 and 8 weeks, respectively. Conclusions: Transscleral iontophoresis is capable of delivering macromolecule drugs through the conjunctiva and sclera, eventually exposing the retina/choroid to the drugs.

01 Feb 2019·Current Eye Research

Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial

Article

Author: Higuchi, John W. ; Brar, Balbir ; Foster, C. Stephen ; Papangkorn, Kongnara ; Jhaveri, Chirag ; Scales, David K. ; Montieth, Alyssa ; Truett, Kim R. ; Higuchi, William I. ; Vitale, Albert T.

PURPOSEFrequent steroid drops represent a challenge in patient compliance. This study evaluated the safety and efficacy of 5 minute topical dexamethasone sodium phosphate-Visulex (DSP-Visulex) treatment regimen (two applications on the first week then weekly after) compared to daily prednisolone acetate 1% (PA) for noninfectious anterior uveitis.MATERIALS AND METHODSForty-four patients were randomized to 8% DSP-Visulex with placebo eye drops (8% group, n = 14), 15% DSP-Visulex with placebo eye drops (15% group, n = 15), or Vehicle-Visulex with PA eye drops (PA group, n = 15). Patients received daily eye drops and Visulex treatments on days 1, 3, 8, and 15 with an optional treatment on day 22. Efficacy measures were change in anterior chamber cell (ACC) count from baseline and proportion of patients with zero ACC count at days 8, 15, and 29. Safety measures were adverse events (AEs), visual acuity, ocular symptoms, and intraocular pressure (IOP).RESULTSACC resolution over time was similar among the three groups. The percentage of patients with clear ACC was 18%, 22%, and 15% on day 8; 27%, 56%, and 54% on day 15; and 90%, 88%, and 77% on day 29 for the 8%, 15%, and PA groups, respectively. The numbers of reported AEs were 10, 36, and 12 for the 8%, 15%, and PA groups, respectively. Ten patients among all groups experienced treatment-related AEs, which included headache, eye pain, corneal abrasion, conjunctival/corneal staining, conjunctivitis, visual acuity reduction, and keratitis all of which were resolved during the timeframe of patients' participation in the study. IOP elevation was noted in the PA group throughout the study, whereas IOP elevation in the DSP-Visulex groups was observed at day 3 but not thereafter.CONCLUSIONSThe efficacy of the DSP-Visulex applications was comparable to the daily PA drops in the treatment of noninfectious anterior uveitis. Both 8% and 15% DSP-Visulex treatments were safe and well tolerated.

01 May 2018·Journal of Ocular Pharmacology and TherapeuticsQ4 · MEDICINE

Ocular Drug Distribution and Safety of a Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in Rabbit

Q4 · MEDICINE

Article

Author: Brar, Balbir ; Higuchi, John W. ; Papangkorn, Kongnara ; Higuchi, William I.

PURPOSETo determine the ocular toxicity, systemic exposure, and amounts of dexamethasone sodium phosphate (DSP) in ocular tissues after administration of DSP with the Visulex system (DSP-Visulex).METHODSDSP-Visulex was applied onto healthy rabbit eyes. DSP concentrations (4%, 8%, 15%, and 25%) and treatment durations (5, 10, and 20 min) were evaluated for the amounts of DSP in the ocular tissues and in plasma after single administrations of DSP-Visulex. The drug in eye tissues and plasma was analyzed by high-performance liquid chromatography-UV/VIS and by liquid chromatography-mass spectrometry, respectively. The safety and tolerability were ascertained based on clinical observations and histopathological examinations from repeat weekly DSP-Visulex treatments (4%, 8%, 15%, and 25% for 20 min) for 12 weeks.RESULTSSignificant amounts of DSP (ie, higher than 1 μg/g) were found in the anterior chamber, retina-choroid, cornea, vitreous, conjunctiva, and sclera after single applications of DSP-Visulex. The DSP concentrations in the ocular tissues and in plasma increased with increased DSP concentrations in the Visulex applicator and with increased application times. Systemic DSP was rapidly detected. The plasma half-life was 2-3 h. C_max was 148 and 1,844 ng/mL, and the area under the plasma drug concentration versus time curve (AUC) was 418 and 3,779 ng · h/mL for the low dose (4% DSP-Visulex for 5 min) and the high dose (15% DSP-Visulex for 20 min), respectively. Ocular findings over 12 weeks were mostly conjunctival injection and eye discharge. These were transient and mild. Histopathological examinations indicated the eyes to be normal.CONCLUSIONSDSP can be administered safely and effectively into the rabbit eye with the Visulex system. Treatment duration and DSP concentration are important factors in achieving therapeutic levels. Repeat applications of DSP-Visulex are safe and well tolerated for weekly administrations over 4-12 weeks. DSP-Visulex has clinical potential for the noninvasive treatment of ocular diseases.

News (Medical) associated with Aciont, Inc.

24 Feb 2021

·www.globenewswire.com

Anterior Uveitis Treatment Market Research Report by Treatment Type, by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19

New York, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Anterior Uveitis Treatment Market Research Report by Treatment Type, by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19" - Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Anterior Uveitis Treatment Market is expected to grow from USD 201.59 Million in 2020 to USD 289.82 Million by the end of 2025.2. The Global Anterior Uveitis Treatment Market is expected to grow from EUR 176.75 Million in 2020 to EUR 254.11 Million by the end of 2025.3. The Global Anterior Uveitis Treatment Market is expected to grow from GBP 157.13 Million in 2020 to GBP 225.91 Million by the end of 2025.4. The Global Anterior Uveitis Treatment Market is expected to grow from JPY 21,514.76 Million in 2020 to JPY 30,931.13 Million by the end of 2025.5. The Global Anterior Uveitis Treatment Market is expected to grow from AUD 292.73 Million in 2020 to AUD 420.85 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Anterior Uveitis Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Treatment Type, the Anterior Uveitis Treatment Market studied across Anti-TNF Agents, Corticosteroids, Cycloplegic Agents, and Immunosuppressants. Based on Distribution Channel , the Anterior Uveitis Treatment Market studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Based on Geography, the Anterior Uveitis Treatment Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Anterior Uveitis Treatment Market including AbbVie Inc., Aciont Inc., Akorn Pvt. Ltd, Aldeyra Therapeutics, Inc., Alimera Sciences Inc., Amdipharm Mercury Company Limited, Amgen Inc., Bausch & Lomb Incorporated, Clearside Biomedical, Inc., Enzo Biochem Inc, Enzo Biochem Inc., Eyegate Pharmaceuticals, Inc., Hanall Biopharma, Lux Biosciences, Inc, Novartis AG, Ophthalix Inc, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co. Ltd, Sirion Therapeutics, Inc., TopiVert Pharma Limited, UAB Medicine, UCB Biopharma S.P.R.L., Wize Pharma Inc, and Xoma Corporation. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anterior Uveitis Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Anterior Uveitis Treatment Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anterior Uveitis Treatment Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anterior Uveitis Treatment Market?4. What is the competitive strategic window for opportunities in the Global Anterior Uveitis Treatment Market?5. What are the technology trends and regulatory frameworks in the Global Anterior Uveitis Treatment Market?6. What are the modes and strategic moves considered suitable for entering the Global Anterior Uveitis Treatment Market?Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

Acquisition

100 Deals associated with Aciont, Inc.

100 Translational Medicine associated with Aciont, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DSP-Visulex	Uveitis, Anterior More	Phase 2
AMD program	Age Related Macular Degeneration More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis